GGrantIndex
← Leaderboards

Li Zhang

American National Red Cross

$7,762,730
Attributed
$7,762,730
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $883.3K · FY200925
$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,762,730 · 8

By mechanism

R01$7,321,255 · 5
R21$410,625 · 1
R13$30,850 · 1
P01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at American National Red Cross

Same institution · by research overlap

Others in their field

Top investigators on “Integrins

Research focus

IntegrinsDesignMolecularMacrophage-1 AntigenMacrophageMediatingIn VivoCellsExhibitsResponseHomologous GeneMouse ModelFibrinBaseVariantSignal TransductionScanningMutantInsightPlayAutoimmune DiseasesReceptorItgam GeneReporting

Grant awards (26)

Cell type-specific roles of integrin CD11b in atherosclerosis regression$752,709
R01 · FY2025 · HL · contact PI
2024 Plasminogen Activation and Extracellular Proteolysis Gordon Research Conference and Gordon Research Seminar$30,850
R13 · FY2024 · HL · contact PI
Ligand-dependent and cell type-specific functions of integrin CD11b/CD18 in multiple sclerosis$415,135
R01 · FY2023 · NS · contact PI
Targeting the Proinflammatory Activity of Integrin Mac-1 for Treatment of Atherosclerosis$468,174
R01 · FY2022 · HL · contact PI
Microglial Mac-1 protects against the development of ADRD by enhancing TREM-2 expression$386,248
R01 · FY2022 · HL · contact PI
Ligand-dependent and cell type-specific functions of integrin CD11b/CD18 in multiple sclerosis$1
R01 · FY2022 · NS · contact PI
Targeting the Proinflammatory Activity of Integrin Mac-1 for Treatment of Atherosclerosis$468,174
R01 · FY2021 · HL · contact PI
Ligand-dependent and cell type-specific functions of integrin CD11b/CD18 in multiple sclerosis$415,135
R01 · FY2021 · NS · contact PI
Targeting the Proinflammatory Activity of Integrin Mac-1 for Treatment of Atherosclerosis$468,174
R01 · FY2020 · HL · contact PI
Ligand-dependent and cell type-specific functions of integrin CD11b/CD18 in multiple sclerosis$415,135
R01 · FY2020 · NS · contact PI
Targeting the Proinflammatory Activity of Integrin Mac-1 for Treatment of Atherosclerosis$463,539
R01 · FY2019 · HL · contact PI
Ligand-dependent and cell type-specific functions of integrin CD11b/CD18 in multiple sclerosis$413,223
R01 · FY2019 · NS · contact PI
Mac-1 coordinates PDGF-CC activation by microglia and promotes BBB opening$335,781
R01 · FY2017 · NS · contact PI
Mac-1 coordinates PDGF-CC activation by microglia and promotes BBB opening$335,781
R01 · FY2016 · NS · contact PI
Mac-1 coordinates PDGF-CC activation by microglia and promotes BBB opening$335,781
R01 · FY2015 · NS · contact PI
Mac-1 coordinates PDGF-CC activation by microglia and promotes BBB opening$332,422
R01 · FY2014 · NS · contact PI
Mac-1 coordinates PDGF-CC activation by microglia and promotes BBB opening$335,781
R01 · FY2013 · NS · contact PI
Integrin CD11b and its role in immune suppression$185,625
R21 · FY2010 · AI · contact PI
Integrin CD11b and its role in immune suppression$225,000
R21 · FY2009 · AI · contact PI
LIGAND BINDING AND ACTIVITY MODULATION OF INTEGRIN MAC-1$150,884
R01 · FY2003 · HL
LIGAND BINDING AND ACTIVITY MODULATION OF INTEGRIN MAC-1$105,100
R01 · FY2003 · HL
LIGAND BINDING AND ACTIVITY MODULATION OF INTEGRIN MAC-1$248,529
R01 · FY2002 · HL
Modulation of integrin function by the urokinase receptor$0
P01 · FY2002 · HL
LIGAND BINDING AND ACTIVITY MODULATION OF INTEGRIN MAC-1$241,288
R01 · FY2001 · HL
Modulation of integrin function by the urokinase receptor$0
P01 · FY2001 · HL
LIGAND BINDING AND ACTIVITY MODULATION OF INTEGRIN MAC-1$234,261
R01 · FY2000 · HL